Side-polished SMF |
SPR |
Au layer+SAM+antigen LP |
Legionella pneumophila (LP) |
[23] |
LOD 101 CFU (colony forming unit)/ml |
Side-polished SMF |
SPR |
Au layer+SAM+antigen SEB |
Staphylococcal enteroxin B (SEB) |
[24] |
LOD 10 ng/ml |
Unclad MMF |
SPR |
Ag layer+lipase enzyme |
Triacylglycerides |
[78] |
S 3.17 nm/mM in the range 0.5–7.0 mM |
Unclad MMF |
SPR |
Ag, Si layers+enzyme gel |
Urea |
[79] |
S < 0.2 nm/mM in the range 0–160 mM |
Unclad MMF |
SPR |
Au layer+4-aminothiophenol+anti-apolipoprotein B |
Low-density lipoprotein (LDL) |
[80] |
S 0.18 nm/(mg/dl) in the range 0–190 mg/dl |
Unclad MMF |
SPR |
Ag layer+tyrosinase gel |
Phenolic compounds in aqueous samples |
[81] |
LOD 38 μm for phenol to 100 μm for catechol |
Unclad MMF |
SPR |
Au layer+nanobeads+polyclonal Ara h1 antibody |
Ara h1 peanut allergens in complex food matrices |
[82] |
LOD 0.09 μg/ml (with nanobead enhanced assay) |
Unclad MMF |
SPR |
Au layer+SAM+streptavidin+biotinylated ssDNA aptamers |
DNA hybridization assay |
[83] |
Human immunoglobulin E (hIgE) |
LOD 2 nm |
Unclad MMF |
SPR |
Au layer+ssDNA+AuNP modified ssDNA |
Genetic mutations in PCR amplified DNA of bacterium Legionella pneumophila
|
[84] |
LOD 1 nm |
Unclad MMF |
SPR |
Au layer+SAM+streptavidin+biotinylated eGFP (enhanced green fluorescence protein) |
p3 and p8 bacteriophages binding |
[85] |
Kinetic analysis |
TFBGs |
SPR |
Au layer+thiol-modified aptamers |
Thrombin in buffer and serum solutions |
[66, 86] |
LOD 22 nm |
TFBGs |
SPR |
Au layer+SAM+anti-transferrins |
Transferrin |
[87] |
LOD 10−6 g/ml |
TFBGs |
SPR |
Au layer+fibronectin |
Analysis of cellular behavior under different stimuli |
[88] |
Specialty fiber |
SPR |
Ag layer+SAM+biotin+neutravidin+biotinylated anti-CLU IgG and anti-apoE IgG |
Gastric cancer biomarkers: apolipoprotein E (apoE) and clusterin (CLU) |
[89] |
Two cascaded sensing regions |
End face MMF |
LSPR |
Spherical Au NPs+anti-IFN-γ and anti-PSA |
Interferon-γ (IFN-γ) and prostate-specific antigen (PSA) |
[90] |
LOD 2 pg/ml for IFN-γ and 1 pg/ml for PSA |
End face SMF |
LSPR |
Au nanodisks+SAM+mouse anti-human PSA |
Free prostate specific antigen (f-PSA) |
[91] |
LOD 100 fg/ml (ca. 3 fM) |
U-shaped |
LSPR |
Spherical Au NPs+glucose oxidase |
Blood glucose |
[92] |
Intensity changes in the range 0–250 mg/dl |
Unclad MMF |
LSPR |
Spherical Au NPs+SAM+anti-IL-1β |
Interleukin-1β (IL-1β) in synovial fluids |
[93] |
LOD 21 pg/ml (1.2 pM) |
Unclad MMF |
LSPR |
Au nanorods/nanospheres+human IgG |
Anti-human immunoglobulin G (IgG) |
[94] |
LOD 1.6 nm |
Unclad MMF |
LSPR |
Spherical Au NPs+anti-TNF-α and anti-MMP-3 |
Tumor necrosis factor-α (TNF-α) and matrix metalloproteinases-3 (MMP-3) in synovial fluid |
[95] |
LOD 8.2 pg/ml (0.48 pM) and 34 pg/ml (1.6 pM) |
Unclad MMF |
LSPR |
Au nanorods+anti-CymMV and anti-ORSV |
Cymbidium mosaic virus (CymMV) Odontoglossumringspot virus (ORSV) |
[96] |
LOD 48 pg/ml for CymMV and 42 pg/ml for ORSV |
Unclad POF |
LSPR |
Au NPs+anti SARS-CoV N proteins |
Severe acute respiratory syndrome (SARS) coronavirus (CoV) nucleocapsid protein (N protein) in human serum |
[97] |
LOD 1 pg/ml |
TFBGs |
LSPR |
APTMS, glutaraldehyde and cysteamine thin films+Au nanocages/nanospheres |
Biotin |
[98] |
LOD 11 pM (nanospheres) to 8 pM (nanocages) |
PCF+FBG |
LSPR |
Oligonucleotide-functionalized Au NPs |
DNA target sequences |
[99] |
Unclad MMF |
SPR |
Ag or Au layer+silicon+bromocresol purple |
Ammonia |
[100] |
LOD 10 ppm |
Unclad MMF |
SPR |
Au layer+SiO2+Palladium |
Hydrogen |
[101] |
LOD 0.5 % |
Unclad MMF |
SPR |
Pd layer for H2
|
H2, H2S, and H2O |
[102] |
Ag layer for H2S |
Au+SiO2 for moisture |
U-shaped |
LSPR |
Au NPs+4-mercaptobenzoic acid (4-MBA)+l-cysteine+cysteamine |
Nitro-based explosive molecules |
[103] |
LOD ppb for TNT vapors |